About denali therapeutics inc - DNLI
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
DNLI At a Glance
Denali Therapeutics, Inc.
161 Oyster Point Boulevard
San Francisco, California 94080
| Phone | 1-650-866-8547 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -422,773,000.00 | |
| Sector | Health Technology | Employees | 422 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
DNLI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.364 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -5.21 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.021 |
DNLI Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,001,831.754 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
DNLI Liquidity
| Current Ratio | 8.458 |
| Quick Ratio | 8.458 |
| Cash Ratio | 8.144 |
DNLI Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -33.446 |
| Return on Equity | -37.403 |
| Return on Total Capital | -32.926 |
| Return on Invested Capital | -36.013 |
DNLI Capital Structure
| Total Debt to Total Equity | 4.418 |
| Total Debt to Total Capital | 4.231 |
| Total Debt to Total Assets | 3.953 |
| Long-Term Debt to Equity | 3.439 |
| Long-Term Debt to Total Capital | 3.293 |